Prehospital Ticagrelor in ST-Segment Elevation Myocardial Infarction
Author(s) -
Gilles Montalescot,
Arnoud W.J. van ’t Hof,
Frédéric Lapostolle,
Johanne Silvain,
Jens Flensted Lassen,
Leonardo Bolognese,
Warren J. Cantor,
Ángel Cequier,
Mohamed Chettibi,
Shaun G. Goodman,
Christopher Hammett,
Kurt Huber,
Magnus Janzon,
Béla Merkely,
Robert F. Storey,
Uwe Zeymer,
Olivier Stibbe,
Patrick Ecollan,
Wim M.J.M. Heutz,
Eva Swahn,
JeanPhilippe Collet,
Frank F. Willems,
Caroline Baradat,
Muriel Licour,
Anne Tsatsaris,
Éric Vicaut,
Christian W. Hamm
Publication year - 2014
Publication title -
new england journal of medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 19.889
H-Index - 1030
eISSN - 1533-4406
pISSN - 0028-4793
DOI - 10.1056/nejmoa1407024
Subject(s) - medicine , ticagrelor , percutaneous coronary intervention , myocardial infarction , cardiology , prasugrel , conventional pci , thrombolysis , angioplasty , adverse effect , st segment , interventional cardiology
The direct-acting platelet P2Y12 receptor antagonist ticagrelor can reduce the incidence of major adverse cardiovascular events when administered at hospital admission to patients with ST-segment elevation myocardial infarction (STEMI). Whether prehospital administration of ticagrelor can improve coronary reperfusion and the clinical outcome is unknown.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom